EUVIMEDEUVIMED entdecken
Crossref

Intermediate‐Risk Papillary Thyroid Cancer: Not Everyone Needs Radioactive Iodine

Ignacio Fuentes iD, Marlín Solórzano iD, Annette Madison iD, Joel Falcón, Catalina Ruiz, Joaquín Viñambres iD, Rodolfo Cabello iD, Nicole Lustig iD, Lorena Mosso iD, Rodrigo Jaimovich, Juan Carlos Quintana iD, Francisco Domínguez iD und 5 weitere

Clinical Endocrinology · 19.07.2026

DOI: 10.1111/cen.70180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, online erschienen am 19.07.2026. Verfasst von Ignacio Fuentes und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Cancer, Papillary, Thyroid Neoplasms. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Intermediate‐risk papillary thyroid carcinoma (PTC) accounts for 40%–60% of newly diagnosed PTC and comprises a heterogeneous group with variable recurrence risk. The benefit of postoperative radioactive iodine (RAI) remains uncertain.

Objectives

To describe features, response‐to‐therapy outcomes, and ATA 2025 recurrence‐risk redistribution in patients with ATA 2015 intermediate‐risk PTC managed without adjuvant RAI.

Design

Retrospective cohort study.

Methods

Adults (≥ 18 years) with ATA 2015 intermediate‐risk PTC treated with total thyroidectomy (TT) or thyroid lobectomy (TL), with/without lymph node dissection, and followed for ≥ 1 year were included. Omission of postoperative RAI was based on histopathology, cervical ultrasound (US), serum thyroglobulin (Tg), and anti‐thyroglobulin antibodies (TgAb) measured within 6 months postoperatively. TL patients required negative US. TT patients required negative US plus Tg < 1 ng/mL if TgAb‐negative, or stable/declining TgAb if positive. Response to therapy was assessed using ATA 2015 dynamic risk stratification and reassessed with ATA 2025 criteria.

Results

Ninety‐nine patients were included; 84 (84.8%) were women, the mean age was 40.2 ± 13.3 years, and the median follow‐up was 4.8 years. Microscopic extrathyroidal extension was present in 51 (51.5%), lymph node metastases in 37 (37.4%), and extranodal extension in 4 (4.0%). By ATA 2015, 67 (67.7%) had an excellent response and 32 (32.3%) an indeterminate response; no incomplete responses or structural recurrences occurred. ATA 2025 reclassified 3 (3.0%) as low risk, 39 (39.4%) as low‐intermediate, 52 (52.5%) as high‐intermediate, and 5 (5.1%) as high risk.

Conclusions

Selected intermediate‐risk PTC patients managed without adjuvant RAI had excellent mid‐term outcomes, supporting a risk‐adapted de‐escalation strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iodine RadioisotopesThyroid Cancer, PapillaryThyroid NeoplasmsHumansFemaleAdultMiddle AgedRetrospective StudiesThyroidectomyMaleNeoplasm Recurrence, LocalThyroglobulin

Stichwörter der Autor:innen

dynamic risk stratificationintermediate riskpapillary thyroid carcinomaradioactive iodine

Substanzen

Iodine RadioisotopesThyroglobulin

Autor:innen und Institutionen

  • Department of Endocrinology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • CETREN-UC, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Department of Nuclear Medicine, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Department of Head and Neck Surgery, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Department of Radiology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Department of Pathology, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.

ORCID-Profile: Ignacio Fuentes, Marlín Solórzano, Annette Madison, Joaquín Viñambres, Rodolfo Cabello, Nicole Lustig, Lorena Mosso, Juan Carlos Quintana, Francisco Domínguez, Pablo H Montero, José M Domínguez

Zitieren

APA

Fuentes, I., Solórzano, M., Madison, A., Falcón, J., Ruiz, C., Viñambres, J., Cabello, R., Lustig, N., Mosso, L., Jaimovich, R., Quintana, J. C., Domínguez, F., González, H. E., Montero, P. H., Cruz, F., Solar, A., & Domínguez, J. M. (2026). Intermediate‐Risk Papillary Thyroid Cancer: Not Everyone Needs Radioactive Iodine. Clinical Endocrinology. https://doi.org/10.1111/cen.70180

Vancouver

Fuentes I, Solórzano M, Madison A, Falcón J, Ruiz C, Viñambres J, et al. Intermediate‐Risk Papillary Thyroid Cancer: Not Everyone Needs Radioactive Iodine. Clinical Endocrinology. 2026. doi:10.1111/cen.70180

BibTeX
@article{Fuentes2026,
  author = {Fuentes, Ignacio and Solórzano, Marlín and Madison, Annette and Falcón, Joel and Ruiz, Catalina and Viñambres, Joaquín and Cabello, Rodolfo and Lustig, Nicole and Mosso, Lorena and Jaimovich, Rodrigo and Quintana, Juan Carlos and Domínguez, Francisco and González, Hernán E and Montero, Pablo H and Cruz, Francisco and Solar, Antonieta and Domínguez, José M},
  title = {Intermediate‐Risk Papillary Thyroid Cancer: Not Everyone Needs Radioactive Iodine},
  journal = {Clinical Endocrinology},
  year = {2026},
  doi = {10.1111/cen.70180}
}
Kostenlos starten →